Effect of indapamide on phosphate metabolism and vascular reactivity

Plante, Gérard E.; Lafreniere, Marie-Chantal; Tam, Pham Thi; Sirois, Pierré

doi:10.1016/0002-9343(88)90809-1

Cited by 7 publications

(2 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Diuretic therapy may lead to potassium, magnesium and phosphate depletion as a result of urinary losses, which reflect a direct effect of diuretics on the homeostasis of these electrolytes (40–42). Furthermore, experimental and clinical observations have demonstrated a close link among potassium, magnesium and phosphate concentrations (43–46).…”

Section: Electrolyte Disorders Related To Antihypertensive Therapymentioning

confidence: 99%

“…Hypophosphataemia because of renal losses is observed after inhibition of carbonic anhydrase with acetazolamide. Thiazides and indapamide can produce an increase in the renal clearance of inorganic phosphate and hypophosphataemia (41,42). The underlying mechanisms may involve a direct effect of the diuretic on distal renal tubular reabsorption of phosphate, as well changes in potassium and/or magnesium homeostasis.…”

Section: Electrolyte Disorders Related To Antihypertensive Therapymentioning

confidence: 99%

See 1 more Smart Citation

Blood pressure drug therapy and electrolyte disturbances

Liamis

Milionis

Elisaf

2008

International Journal of Clinical Practice

View full text Add to dashboard Cite

Antihypertensive pharmacologic treatment may be associated with diverse disturbances of electrolyte homeostasis. These drug-induced disorders are relatively common, typically including hyponatraemia, hypokalaemia, hyperkalaemia, hypomagnesaemia, hypophosphataemia and hypercalcaemia. Diuretics, beta-blockers, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are particularly likely to cause these complications. Recognised risk factors include high-dosage regimens (especially diuretics), old age, diabetes and impairment of renal function. Strategies to prevent these adverse drug reactions involve careful consideration of risk factors and clinical and laboratory evaluation in the course of treatment.

show abstract

Section: Electrolyte Disorders Related To Antihypertensive Therapymentioning

confidence: 99%

Section: Electrolyte Disorders Related To Antihypertensive Therapymentioning

confidence: 99%

Blood pressure drug therapy and electrolyte disturbances

Liamis

Milionis

Elisaf

2008

International Journal of Clinical Practice

View full text Add to dashboard Cite

show abstract

Comparison of indapamide and hydrochlorothiazide plus amiloride as a third drug in the treatment of arterial hypertension

Poulsen

Friberg

Noer

et al. 1989

Cardiovasc Drug Ther

View full text Add to dashboard Cite

In a randomized, double-blind crossover trial, indapamide (IND) 2.5 mg and hydrochlorothiazide 25 mg + amiloride 2.5 mg (HCTZ + A) were found to be equally effective in reducing blood pressure (BP) in 13 patients with moderate to severe hypertension already receiving chronic treatment with a beta blocker and a vasodilatator (supine BP during run-in: 169/103 +/- 21/5 mmHg; on IND: 149/91 +/- 21/14 mmHg; on HCTZ + A 144/88 +/- 23/5 mmHg). Both drugs induced insignificant reductions in body weight, and no change in plasma volume was seen. Serum potassium was significantly reduced on both regimens--the values recorded on IND being significantly lower than those seen on HCTZ + A. Values below 3.0 mmol/l were found in two patients receiving IND, but no subjective side effects were reported. Hyperuricemia occurred with the same frequency on both regimens. It is concluded that IND, just like the thiazide diuretics, is useful as the third drug in patients needing triple drug therapy to control BP, but metabolic adverse effects are not avoided by the choice of this drug.

show abstract